key: cord-0980254-csd08t2v
authors: C, Chevillard; A, Amen; S, Besson; D, Hannani; I, Bally; V, Dettling; E, Gout; CJ, Moreau; M, Buisson; S, Gallet; D, Fenel; E, Vassal-Stermann; G, Schoehn; P, Poignard; MC, Dagher; P, Fender
title: Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform
date: 2022-02-10
journal: Mol Ther
DOI: 10.1016/j.ymthe.2022.02.011
sha: decc4213b244cd32be44a80c5ca0190951d330bb
doc_id: 980254
cord_uid: csd08t2v

Virus like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a SpyTag/SpyCatcher system. To validate the platform as a potential COVID-19 vaccine approach, we decorated the newly designed VLP with the glycosylated receptor binding domain (RBD) of SARS-CoV-2. Cryo-Electron Microscopy structure revealed that up to 60 copies of this antigenic domain could be bound on a single ADDomer particle, with the symmetrical arrangements of a dodecahedron. Mouse immunization with the RBD decorated VLPs already showed a significant specific humoral response following prime vaccination, greatly reinforced by a single boost. Neutralization assays with SARS-CoV-2 spike pseudo-typed-virus demonstrated the elicitation of strong neutralization titers, superior to those of COVID-19 convalescent patients. Notably, the presence of pre-existing immunity against the adenoviral-derived particles did not hamper the immune response against the antigen displayed on its surface. This plug and play vaccine platform represents a promising new highly versatile tool to combat emergent pathogens.

Virus like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present 27 work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer 28 dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a 29 SpyTag/SpyCatcher system. To validate the platform as a potential COVID-19 vaccine 30 approach, we decorated the newly designed VLP with the glycosylated receptor binding domain 31 (RBD) of SARS-CoV-2. Cryo-Electron Microscopy structure revealed that up to 60 copies of 32 this antigenic domain could be bound on a single ADDomer particle, with the symmetrical 33 arrangements of a dodecahedron. Mouse immunization with the RBD decorated VLPs already 34 showed a significant specific humoral response following prime vaccination, greatly reinforced 35 by a single boost. Neutralization assays with SARS-CoV-2 spike pseudo-typed-virus 36 demonstrated the elicitation of strong neutralization titers, superior to those of COVID-19 37 convalescent patients. Notably, the presence of pre-existing immunity against the adenoviral-38 derived particles did not hamper the immune response against the antigen displayed on its 39

surface. This plug and play vaccine platform represents a promising new highly versatile tool 40 to combat emergent pathogens. 41

Although genomic vaccine have recently demonstrated their capacity to elicit protective 49 immune responses, 1 protein-based vaccines remain highly attractive due to their lower cost, 50 ease of transport and storage, crucial to reach developing countries and remote locations, as 51 well as better social acceptation, as recently highlighted by hesitancy regarding COVID-19 52 RNA vaccines. Protein immunogenicity is highly increased through presentation to the immune 53 system in a multimeric manner and a number of vaccine platforms have been developed to this 54 aim, with various advantages and limitations. 2 We have previously reported that a non-55 infectious virus like particle (VLP) derived from human Adenovirus of type 3 and consisting 56 of 60 identical penton base monomers could be exploited to display epitopes of interest on its 57 surface. [3] [4] [5] In this vaccine platform, named ADDomer, exposed loops of the penton base protein 58 were engineered to allow insertion of foreign peptides such as a linear neutralizing epitope from 59 Chikungunya virus. However, this design did not permit the insertion of structurally complex 60 antigens. To overcome this limitation while keeping the immunogenicity advantage of 61 ADDomer, we describe here a redesigned platform offering a highly versatile capacity to 62 display large and structurally complex antigens with potential post-translational modifications. 63

In order to decorate the adenovirus-based VLPs with large antigens, the SpyTag/SpyCatcher 64 system 6-9 was combined to the ADDomer technology. In this system, derived from 65 Streptococcus pyogenes, an Aspartate residue from the 13 amino-acid SpyTag peptide (ST) can 66 spontaneously create a covalent bond with a Lysine residue encompassed in the complementary 67

SpyCatcher module (SC). We thus genetically inserted the sequence coding for the ST peptide 68 into the 'variable loop' of the ADDomer that was previously used for small antigen insertion, 69 yielding a VLP with 60 potential attachment sites for complex antigens engineered with an SC 70 anchor. 71 J o u r n a l P r e -p r o o f In order to assess the newly developed platform, we decided to first test it as a potential 72 candidate vaccine to elicit neutralizing antibodies (NAbs) against the severe acute respiratory 73 syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped positive strand RNA 74 virus belonging to the beta-coronavirus genus from the coronaviridae family. It is the etiological 75 agent of COVID-19 and at the origin of the pandemic that started in December 2019, leading 76

to 5 542 359 deaths as of January 19, 2022 (https://covid19.who.int/), and vast socio-economic 77 consequences. 10 Protection against SARS-CoV-2 infection and COVID-19 can be mediated by 78

neutralizing Abs targeting the envelope trimeric glycoprotein spike (S) exposed at the surface 79 of the virus. 11,12 Accordingly, spike-based vaccine approaches eliciting SARS-CoV-2 NAb 80 responses have been successful at preventing The ectodomain of the S protein 81 is divided into the S1 and S2 domains. The Spike protein binds to the host Angiotensin-82

Converting Enzyme 2 (ACE2) which serves as an entry receptor, as previously reported with 83 SARS-CoV, responsible of the 2002 -2004 A subdomain of S1, named 84 receptor binding domain (RBD), is the contact interface between the virus and the ACE2 85 receptor. Numerous studies have shown that the RBD comprises multiple distinct antigenic 86 sites and is a prime target for NAbs in COVID-19 convalescent patients. 20-23 These NAbs 24 87 strongly inhibit cell infection by SARS-CoV-2 by competing with the RBD-ACE2 interaction. 88

Moreover, anti-RBD NAbs have been shown to confer protection against SARS-CoV-2 89 challenge in animal models of COVID-19, as well as to prevent COVID-19 in human, thus 90 confirming the interest of using RBD as a vaccine immunogen. 25,26,27 91 This prompted us to use the RBD as the antigen to be displayed on our newly-designed VLP 92 platform in order to engineer a novel COVID-19 vaccine approach. Here, we report that the 93 newly designed platform can successfully be decorated with SARS-CoV-2 RBD and is highly 94 immunogenic in mice, eliciting high neutralizing Ab titers. 95 96 J o u r n a l P r e -p r o o f

ADDomer is a non-infectious 30 nm nanoparticle, formed from 12 bricks of the homo-99 pentameric penton base from the human adenovirus type 3. The ST sequence was inserted in 100 the ADDomer gene in a region coding for the exposed flexible loop called the variable loop 101 ( Figure 1a ). Due to the spontaneous homo-oligomerization of twelve pentameric penton base, 102 sixty copies of ST are exposed on the surface of the ADDomer-ST (ADD-ST) particle. To 103 assess whether the newly inserted ST sequence was accessible and functional on ADD-ST, 104

incubation with different ratio of SC was performed. After boiling of samples, SDS-PAGE 105 profile clearly showed that the incremental SC/ADD-ST ratio is correlated with the apparition 106 of a band of higher molecular weight and the decrease of the intensity of bands related to 107 unlinked moieties. Importantly, there was no remaining signal for undecorated ADD-ST after 108 SC addition at the highest ratio thus reflecting the full decoration of the nanoparticle ( Figure  109 1b). This result suggests an efficient and concentration-dependent formation of the ADD-110

ST/SC complex. Mass spectroscopy analysis confirmed that the ADD-ST doublet shifted by 111 13,3kDa (Figure 1c ), which corresponds to the molecular weight (MW) of SC. The two peaks 112 observed in mass spectroscopy is due to a second initiation codon in ADD-ST (starting at 113

Methionine 25) without affecting the particle stability 28 and SC can bind to each form 114 indifferently as shown by a similar shift of their MW corresponding to the addition of SC. 115

Negative staining electron microscopy imaging performed on ADD-ST alone and ADD-ST 116 fully decorated by SC showed that the integrity of the particle was not affected by the presence 117 of SC and the grainy appearance of ADD-ST/SC likely reflects the presence of SC at the particle 118 surface ( Figure 1d ). Altogether, these data show that SC cross-linking to ADD-ST is operational 119 and can result in saturated decoration of the nanoparticle. 120 J o u r n a l P r e -p r o o f -

In order to visualize the SC arrangement around the ADDomer particle, a structural study by 122 cryo-electron microscopy was used. Fully decorated ADD-ST/SC particles were imaged on a 123

Glacios electron microscope (Figure 2a ). Image analysis was performed and the obtained 3D 124 structure was compared to the structure of an undecorated ADDomer particle (EMD-0198). An 125 extra-density corresponding to SC bound to the ADDomer 'variable loop' was clearly visible 126 in ADD-ST/SC both in the density slice of the 3D map ( Figure 2b ) and in the isosurface 127 representation of the structure (Figure 2c , purple density and supplementary movie). The 128 resolution of the ADDomer particle is around 2.8 Å, allowing to clearly see the aminopeptidic 129 chain. However, the ST/SC part is not rigidly attached to the ADDomer, which explain why the 130 corresponding density is fuzzy, and the structure not better defined ( Supplementary Fig.1 ). The 131

ADDomers have 2, 3 and 5 axis of symmetry, (the latter two being shown in Figure 2c ), which 132 is a characteristic of a dodecahedron meaning that SC are distributed accordingly. Interestingly, 133 along the 3-fold axis SC are ~ 4.7 nm apart which is close to the Receptor Binding Domain 134 (RBD) in the trimeric spike protein of SARS-CoV-2 (~ 4.1 nm), suggesting that the decorated 135 particles would closely mimic the natural trimeric arrangement of RBDs ( Figure 2d ). Both the 136 multivalency of SC displayed by the particle and the arrangements they have around the 137 different symmetry axis could be an asset for vaccination purpose if an antigen is fused to this 138 module. 139 -Secreted RBD fused to SC is glycosylated and can be displayed at different ratios 140 on the ADD-ST particle 141

To take advantage of the spontaneous and covalent linking of SC to ADD-ST, we reasoned that 142 SC could be used as a versatile carrier to easily and efficiently fuse antigens, like in this SARS- between a pseudo-typed virus harboring the SARS-CoV-2 spike and either RBD-SC or ADD-181 RBD was performed. Negative control was made with undecorated ADD-ST alone. As 182 expected, both RBD-SC alone and ADD-RBD were able to compete with the pseudo-typed 183 virus with a slightly higher efficiency for the RBD-decorated particle (Fig. 4c) . Altogether, 184 these experiments showed that RBD-SC is properly folded and can bind the ACE2 receptor at 185 the molecular and cellular scales when applied alone (RBD-SC) or linked to the ADDomer 186 particles (ADD-RBD). 187 -RBD-decorated ADDomer elicits rapid anti-CoV2 Ab responses in mice, not 188 negatively impacted by adenovirus pre-immunity 189

Multivalent exposition of RBD antigens at the surface of the particle is likely to result in a better 190 activation of the humoral system than RBD alone. However, one cannot exclude that ADDomer 191 itself could also play an indirect role in the anti-SARS-CoV-2 response, especially in a 192 population with preexisting adenovirus immunity. To address these two points, four groups of 193 ten mice were designed ( Figure 5a ). The two first control groups were injected with alone in the group 1 or with the same amount of unlinked RBD-SC plus naked-ADDomer (i.e. 195 not displaying the antigen) in the group 2. The two other groups (groups 3 and 4) were 196 vaccinated with ADD-RBD (i.e. RBD displayed at the particle surface) but the group 4 was 197 pre-immunized with naked-ADDomer two weeks before the injection of ADD-RBD, in order 198 to investigate whether anti-HAdV-3 penton base antibodies, as may possibly be found in 199 individuals previously infected with adenovirus type 3, may impact the immunogenicity of (RBD-SC alone) or group 2 (ADDomer with not displayed SC-RBD). Interestingly, anti 208

HAdV-3 penton base pre-immunity did not negatively impact the anti-RBD response. A trend 209 towards a stronger anti-RBD response was even observed at this stage. 210

Two weeks after the second immunization (day 27), the anti-RBD response was clearly boosted 213 for groups 3 and 4 that were injected with ADD-RBD, whereas the control groups 1 and 2 214 showed more heterogeneous responses (Figure 6a ). This observation confirms that our vaccine 215 platform displaying multivalent RBD antigens yields a rapid and efficient humoral response. 216 J o u r n a l P r e -p r o o f

The ADDomer technology applied to RBD antigen also demonstrated a long lasting 217 immunogenic effect with anti-SARS-CoV-2 RBD antibodies remaining at the highest level at 218 day 41 (Figure 6b ). The difference between mice pre-immunized by ADDomer (group 4) or not 219 (group 3) was less pronounced than after the first immunization, both groups reaching high and 220 comparable levels. Altogether, these results showed that the second immunization enabled a 221 high and long-lasting Ab response against the SARS-CoV-2 RBD using the ADDomer platform 222 and that anti-vector pre-immunity is possibly beneficial in particular to the initial responses 223 ( Figure 6c) . 224

Since the RBD is critical for binding to the SARS-CoV-2 receptor ACE2, antibodies elicited 226 through immunization with the RBD (RBD-SC or ADDomer-RBD) can hinder the interaction 227 between the Spike proteins and ACE2, blocking viral entry. The ability to neutralize the virus 228 depends on the affinity of the antibodies for the RBD domain, as well as on the epitope 229 recognized. To assess the potency and efficacy of the antibodies induced in the four immunized 230 groups of mice, the neutralization potency of sera (day 41) from vaccinated mice was assessed 231 using SARS-CoV-2 spike (Wuhan strain) pseudo-typed lentivirus and ACE2-expressing HeLa 232 cells. Only a partial and heterogeneous neutralization was obtained from group 1 and 2 sera in 233 which RBD-SC was not displayed on ADDomer, even after two immunizations (Figure 7a , 234 upper panels). Of note, sera from mice immunized with RBD-decorated ADDomer (groups 3 235 and 4) showed a better neutralization titer after a single immunization than group 1 and 2 after 236 2 immunizations (Supplementary Figure 4) . After the second immunization, strong virus 237 neutralization was observed in all mice from group 3 and 4 ( Figure 7a , lower panels). 238

Neutralization titers (ND50) clearly showed that mice vaccinated with RBD-decorated 239

ADDomer had significantly higher neutralizing activity than mice immunized with the same 240 amount of antigen when not displayed on the platform (Figure 7b ). Moreover, in accordance 241 with the ELISA results (Figure 5c ), the anti-vector response (group 4) slightly increased the 242 neutralization titer compared to the naïve group (group 3), which emphasizes that a pre-existing 243

HAdV-3 penton base immunity could be beneficial for our novel vaccine platform (Figure 7b) . 244

The neutralizing Ab titers reached in group 3 and 4 were overall superior to those from a cohort 245 of convalescent COVID-19 patients composed of 50% mild (oxygen below 2L/min) and 50% 246 severe (ICU) cases, and measured at 6 months after hospitalization (Figure 7b In this study, we designed a novel and highly versatile vaccine platform amenable to large 251 antigens by adapting the SpyTag/SpyCatcher technology to ADDomer, an adenovirus-inspired 252 VLP 5,6 . This technology has already been described for designing VLP-derived vaccine, 253 however in these approaches SC was the moiety grafted to the VLPs while the antigens were 254 fused to the Spy Tag. 7,31 In our novel vaccine technology, we used the opposite configuration 255

with SpyTag insertion in an internal loop of ADDomer, which minimized the risk of steric 256 hindrance and functional impact on the spontaneous oligomerization of ADDomers. Insertion 257 of ST in a surface-exposed loop of ADDomer did not impair the spontaneous assembly of 258 twelve pentameric bricks (Figure 1d ), thus creating a universal generic platform for multivalent 259 antigen display. Experiments of saturating cross-linking with SC alone suggested that a full 260 decoration (i.e. 60 copies) of the particle can be achieved (Figure 1b showed an extra density corresponding to the SC interacting with ST fused to the ADDomer. 263

The data thus strongly suggested that the ADDomer could be used to display a multimerized 264 array of antigens, a property that is crucial for the elicitation of strong Ab responses. 32,33,34 265

Interestingly, the characteristic 2, 3 and 5-fold symmetry axis of a dodecahedron are easily 266 visible in the 3D structure (Figure 2c The COVID pandemic led us to first evaluate our newly designed platform as an anti-SARS-271

CoV-2 vaccine to be displayed through fusion to the SC N-terminus. It is worth noting that in 272 the 3-fold axis of ADDomer, the SC adopts a pseudo-trimeric arrangement, which on the RBD 273 decorated VLP closely mimics the tridimensional configuration of this domain in the SARS-274

CoV-2 spike glycoprotein (Figure 2d ). The distance between SC in such configuration is 4,7 275 nm, which is in the same range as that between RBDs in the trimeric Spike protein (4,1 nm). 276

Expressing soluble RBD fused to SC in insect cells resulted in N-glycosylation as expected 35 277 and did not affect the structure of SC, which retained its ability to cross-link to the ADD-ST 278 vaccine platform in a dose dependent manner (Figure 3c ). The proper folding of the 279 glycosylated RBD exposed at the surface of the particles and its ability to bind ACE2 were 280 assessed in a functional viral entry assay via competition with SARS-CoV-2 Spike pseudo-281 typed virions (Figure 4c) . A surface plasmon resonance (SPR) experiment confirmed the high 282 affinity interaction of ADD-RBD to ACE2, the highly stable interaction observed suggesting 283 an avidity effect of the multivalent particle exposing multiple copies of RBD (Figure 4a) . 284

Moreover, this experiment also shows that expressing RBD in insect cell leads to a functional 285 SARS-CoV2 glycoprotein domain. Several vaccines using the baculovirus expression system 286 in insect cells have been approved, such as vaccines against papillomavirus or hepatitis B. The 287

Novavax COVID-19 vaccine candidate, based on an insect cell-produced trimeric S protein, is 288 also advancing towards approval trials. 36 289

The ability of the RBD-decorated ADDomer to elicit an anti-SARS-CoV-2 humoral response 290 was then studied in mice. As expected, we confirmed that displaying the RBD in a multimerized 291 manner led to a strong improvement in immunogenicity (groups 3 and 4 versus groups 1 and 292 2). Indeed, this was clearly apparent from the first injection where the groups with decorated 293 particles showed a significant anti-RBD response at Day 13 as measured in ELISA (Figure 5c) , 294 whereas no response was observed for the other groups. This observation is in agreement with 295 experiments reported with other vaccine platforms that showed that injection of RBD or S-296 trimer alone did not produce significant responses. 31,37 In our experiment, we chose to inject 297 5g of RBD but a dose-response study would be necessary to determine the optimal amount. 298

As a comparison, similar experiments carried out with a similar 60-mer platform showed that 299 0.9 g instead of 5 g of RBD resulted in a similar immune response paving the way to dose-300 sparing. 38 After the second immunization, although a response was observed in the non-301 decorated groups, the titers attained in the decorated groups were about 10 fold greater ( Figure  302 6a). Notably, the anti-RBD response in the latter groups endured over time with similar titers 303 at 2 and 4 weeks following the second immunization ( Figure 6b ). The anti-SARS-CoV-2 RBD 304 sera were further assessed for their capacity to neutralize S-protein pseudotyped lentivirus 305 particles ( Figure 7) . As seen for binding responses, a neutralizing activity was observed in the 306 RBD-decorated groups after the first immunization. Overall, a good correlation between ELISA 307 and neutralizing titers was observed. Strong neutralizing titers were attained in all mice 308 immunized with ADD-RBD after the boost immunization, superior to those of convalescent 309 COVID-19 patients (Figure 7b) , showing the ability of our vaccine platform to elicit functional 310

Ab responses with a potential protective activity. The low titers obtained in mice immunized 311 with RBD and naked ADDomer (no decoration) again demonstrated that the high 312 immunogenicity achieved with decorated VLPs originated from the multimeric display of the 313 antigen. A limitation of our study is that cellular responses were not measured. It is known that 314 CD8 T cell responses likely play an important role in protecting against severe forms of 315 COVID-19. In contrast to mRNA and viral vector vaccines, VLPs are not optimal platforms to 316 elicit CD8 T cell responses, due to the lack of endogenous antigen production. This hurdle may 317 indeed represent a limitation for such vaccines, including our approach. However, CD8 318 responses may be elicited by VLPs under certain circumstances through cross-presentation 319 following uptake by dendritic cells and additional work will be necessary to evaluate whether 320

ADDomer may potentially elicit specific CD8 T cells. Overall, the data are in adequacy with results obtained with similar vaccine platforms using 323 multimeric display of the SARS-CoV-2 RBD on scaffolds such as the 24mer-ferritin, the 60-324 mer dodecahedral thermophilic aldolase. 31, 39, 40, 41 In contrast to these latter vaccine platforms, 325 our particles originate from a human virus, Adenovirus serotype 3 (HAd3), which is known to 326 have a relatively high seroprevalence. 42,43 327

However, if HAdV-3 is globally among the most common types implicated in HAdV infections 328 a great variation is observed by geographic regions. Indeed, HAdV-3 accounts for 15 to 87% 329 of adenoviral respiratory infections with a greater prevalence in Asia than in Western 330 countries. 44 Neutralizing antibodies against HAdV-3 are mainly directed against the hexon 331 protein which is not present in ADDomer made only of penton bases. 332

A potentially detrimental impact of preexisting immunity on the immunogenicity of 333 adenovirus-based viral vectors has been described, 45,46 which thus led us to explore whether 334 such effect may also be encountered with our adenovirus-derived VLP platform. Interestingly, 335 in contrast to adenovirus-viral vectors, pre-immunity against the VLP had no detrimental effect 336 on the immunogenicity of our adenovirus-inspired VLP platform. Indeed, mice with immunity 337

to ADDomer at the time of the first immunization appeared to respond with somehow greater 338

Ab titers against RBD than naive mice, although the difference was not found significant (group 339 4 versus group 3, Figure 5c ). This potential beneficial effect may be in particular explained by 340 the formation of immune complexes leading to a better uptake by antigen presenting cells, via 341

Fc receptors, resulting in an increase in immunogenicity. 47 Of note, the prevalence, in 342 individuals who have been infected with HAdV-3, of antibodies directed against the penton 343 base, which is the only component of ADDomer, is not precisely known. Our present work 344 anticipates that our platform could be used whatever the HAdV-3 immunological status of the 345 patients, and the potential presence of anti-penton antibodies. 346

In conclusion, we designed a new adenovirus-inspired VLP platform that achieves high 347 immunogenicity against the displayed antigen. In contrast to current platforms using the ST/SC 348 system, we opted to engineer the ST on the VLP side, within the exposed VL. Thanks to this 349 design, it can be envisaged to add another ST in a second exposed loop such as the RGD 350 (RGDL), to further increase stoichiometry (up to 120 attachment sites). Moreover, for mosaic 351 vaccine approaches, the RGDL can be used to insert another orthogonal attachment site such 352 as a snoop tag to display a second antigen. As an added value, the use of two different 353 attachment tags/loops allows for differential antigenic stoichiometries and display patterns. 354

Indeed, the RGDLs are more central on the pentameric building block of the ADDomer than 355 the VLs, which are exposed on the periphery, resulting in a greater distance between the VLs 356 than the RGDLs at the pentamer level. Displaying antigens through attachment to these two 357 loops will therefore lead to various patterns of antigen display at the VLP scale as shown in 358

supplementary Figure 5 . This will offer a large range of combinations to vary the stoichiometry 359 of decoration as well as the distance between the antigens to potentially optimize 360 immunogenicity. 48 The versatility of the vaccine platform can thus be exploited to generate 361 mosaic particles displaying RBDs from different betacoronaviruses or SARS-CoV-2 variants 362 to broaden NAb responses and protect against current and future variants of concern. A recent 363 work described that 60-mer mosaic nanoparticles with four to eight distinct RBDs from 364 betacoronaviruses can be generated. Remarkably, the codisplay of the SARS-CoV-2 RBD 365 along with other RBDs showed that the combination of antigens on the same particle did not 366 affect the elicitation of neutralizing antibodies against a particular RBD. 37 Moreover, 367 neutralization of both 'matched' and 'mismatched' strains was observed after mosaic priming 368 suggesting that such particles might protect against several betacoronaviruses at once after a 369 single injection. 370

More generally, our new versatile platform constitutes a putative tool in the preparedness to 371 fight emerging pathogens that will remain to be investigated in viral challenge trials. Pre-immunized group received 2 weeks before the first dose of vaccine (day -15) the ADDomer 479 vector alone (5µg in 100 µl final volume, in the right flank). The day before each vaccination, 480 and 2 and 4 weeks after the last vaccination, 100µl of blood was withdrawn for serologic tests. 481

For retro-orbital blood sampling, mice were anesthetized with 4% Isoflurane. Quantifoil grids (300 mesh, R 1.2/1.3) were negatively glow-discharged at 30 mA for 45 s. 507

3.5 µl of the sample were applied onto the grid, and excess solution was blotted away with a 508 Vitrobot Mark IV (FEI) (blot time: 6 s, blot force: 0, 100% humidity, 20 °C), before plunge-509 freezing in liquid ethane. The grid was transferred onto a 200 kV Thermo Fisher Glacios 510 microscope equipped with a K2 summit direct electron detector for data collection. Automated 511 data collection was performed with SerialEM, acquiring one image per hole, in counting mode. 512

Micrographs were recorded at a nominal ×36,000 magnification giving a pixel size of 1.145 Å 513 (calibrated using a β-galactosidase sample) with a defocus ranging from −0.6 to −2.35 µm. In 514 total, 1038 movies with 40 frames per movie were collected with a total exposure of 40 e−/Å 2 . 515 516 Image processing and cryo-EM structure refinement 517

Movie drift correction was performed with Motioncor2 50 using frames from 2 to 40. CTF 518 determination was performed with Relion 3.1.2 (Scheres 2012). 939 movies out of 1038 were 519 kept at this stage. Particles selection have been done using the Laplacian filter with a diameter 520 between 30 and 40 nm. A total of 77 323 particles have been automatically selected, boxed into 521 480x480 pixel 2 boxes and submitted to 2D classification. After extensive selection and 522

generation of an initial model imposing I1 symmetry, 3D refinement followed by CTF Refine 523 and post-processing generated a final reconstruction including 10163 particles with a resolution 524 of 2.76 Å (Fourier Shell = 0.143) (applied B-factor -82) 525 526

HeLa-ACE2 cells (kindly provided by Dr David Nemazee) were seeded on polylysine coated 528 glass coverslips the day before the experiment. Coverslips were incubated for 1H at 4°C with 529 0.75ug of either ADD-ST or ADD-RBD in 50l of pre-chilled DMEM. Coverslips were washed 530 three time in cold PBS then fixed for 10 minutes with -20°C methanol. Fixed cells were blocked 531 for 1H in PBS supplemented by 3% Normal Goat Serum , then incubated for 1H with 1/1,000 532 rabbit HAd3 anti penton base serum. After three PBS washes cells were incubated with 1/250 533 antiRabbit Alexa488 Ab (ThermoFischer A32721), washed three time in PBS then nuclei were 534 couterstained with Hoechst 33258 for 3 minutes before mounting. Observation were done on 535

Zoe microscope (BioRad). 536 537

Surface plasmon resonance experiment was performed on a T200 instrument. Anti human Fc 539 polyclonal antiboby (Jackson Immunoresearch, 109-005-008) diluted at 25 µg/ml in 10 mM 540 sodium acetate pH 5 was immobilized on CM5 sensor chips using the amine coupling chemistry 541 according to the manufacturer's instructions (Cytiva) to get an immobilization level of 14 000 542 RU. ACE-2 -Fc (GenScript Z033484) was diluted at 1.2µg/ml in HBS P+ (Cytiva) to get an 543 capture level of 100RU. For interaction measurements, ADD-RBD (ranging from 1 nM to 544 11nM in HBSP+) was injected over captured ACE-2 Fc in HBS P+ buffer at 30 µl/min. Anti 545 human Fc polyclonal antiboby flow cell was used for correction of the binding response. 546

Regeneration of the surfaces was achieved by 10mM Glycine pH2. Binding curves were 547 analyzed using BIAEvaluation software (GE Healthcare) and data was fit to a 1:1 Langmuir 548 with drifting baseline interaction model. 549

Pseudovirus production and titration 551

Neutralization assays were performed using lentiviral pseudotypes harbouring the SARS-CoV-552 2 spike and encoding luciferase. Briefly, gag/pol and luciferase plasmids were co-transfected 553 with a SARS-CoV-2 spike plasmid with a C-term deletion of 18aa at 1/0,4/1 ratio on adherent 554 HEK293T cells. Supernatants containing the produced pseudoviruses were harvested 72H after 555 transfection, centrifuged, filtered through 0.45µm and concentrated 50 times on Amicon Ultra 556 (MWCO 100KDa), aliquoted and stored at -80°C. Before use, supernatants were tittered using 557

HeLa ACE-2 cells to determine the appropriate dilution of pseudovirus necessary to obtain 558 about 150 000 RLU per well in a 48 well-plate. 559 560 Neutralization assay 561

Serial 3-fold dilutions starting from 1/10 dilution (serum), or 6µg/mL (known bNAbs) were let 562 in contact with the pseudoviruses for 1h at 37°C in 96-w white plates (Greiner #675083), before 563 addition of HeLa ACE2 cells. Plates were incubated 24h at 37°C, protected from evaporation, 564 then cells were fed with 60 µL of DMEM (Gibco 11966-025) supplemented with 10% FBS ( 565 VWR 97068-086), and incubated for another 24h. Medium in each well was aspirated and 566

replaced by 45 µL of 1X cell lysis buffer (Ozbioscience # LUC1000) for a 60 min-incubation 567 under agitation. Thirty µL of luciferin substrate was then added and Relative Light Unit (RLU) 568 was measured instantly by a luminometer. For competition with ADD-ST, ADD-RBD and 569 RBD-SC the same protocol was used with initial concentration of 150g/mL for ADD-ST, 570

200g/mL and ADD-RBD and 50g/mL for RBD-SC alone. Serums from a cohort of Grenoble 571 region hospitalized convalescent patients were obtained with their consent, 6 to 8 months 572

following COVID-19 diagnosis. The study was approved by the 'Comité de Protection des 573

Personnes SUD-EST I' on 20 August 2020 (ref 2020-84) . 574 575

As the IC50 and ED50 data sets followed a non-normal, heteroscedastic distribution, a non-577 parametric test was used for the different groups comparison. Kruskall-Wallis tests, were 578 performed followed by a Dunn's multiple comparison tests for each figure. Differences were 579 considered significant when p-value was below 0,05. Statistics were performed using GraphPad 580 software, version 9. 

Accelerated COVID-19 592 vaccine development: milestones, lessons, and prospects

Protein-based antigen presentation platforms for 594 nanoparticle vaccines. npj Vaccines 6, 70

Adenovirus dodecahedron, a new vector for human gene transfer

The Adenovirus Dodecahedron: Beyond the Platonic Story

Synthetic self-assembling 601

ADDomer platform for highly efficient vaccination by genetically encoded multiepitope 602 display

Peptide tag forming a rapid covalent bond to a protein, through 605 engineering a bacterial adhesin

Plug-and-Display: decoration of Virus-Like 609 Particles via isopeptide bonds for modular immunization

Structural Analysis and 611 Optimization of the Covalent Association between SpyCatcher and a Peptide Tag

Power to the protein: enhancing and 614 combining activities using the Spy toolbox

A pneumonia outbreak associated with a new coronavirus 617 of probable bat origin

Neutralizing antibody 620 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Correlates of protection against SARS-624

CoV-2 in rhesus macaques

Safety and Efficacy of the 627 BNT162b2 mRNA Covid-19 Vaccine

An 630 mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Efficacy of NVX-633

CoV2373 Covid-19 Vaccine

Structural basis of receptor recognition by SARS-CoV-2

Structural basis for 637 the recognition of SARS-CoV-2 by full-length human ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound 640 to the ACE2 receptor

Deep Mutational 643 Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and 644 ACE2 Binding

Mapping 647 Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding 648 Domain by Structure-Guided High-Resolution Serology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and 652 Recurrent Features of Antibodies

Convergent antibody 655 responses to SARS-CoV-2 in convalescent individuals

Potent 658 neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

CoV-2 neutralizing antibody structures inform therapeutic strategies

A Potently Neutralizing Antibody 665 Protects Mice against SARS-CoV-2 Infection

Potently neutralizing and protective human 668 antibodies against SARS-CoV-2

Antibody Combination to Prevent Covid-19

Structure of the dodecahedral penton particle 674 from human adenovirus type 3

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat 677 Commun 11

Persistence at one year 680 of neutralizing antibodies after SARS-CoV-2 infection: Influence of initial severity and 681 steroid use

A COVID-19 vaccine 684 candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-685 binding domain induces potent neutralising antibody responses

Self-assembling influenza 688 nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

Rational Design of an Epstein-Barr Virus 691 Vaccine Targeting the Receptor-Binding Site

Site-695 specific glycan analysis of the SARS-CoV-2 spike

Efficacy of NVX-CoV2373 Covid-698 19 Vaccine against the B.1.351 Variant

Mosaic nanoparticles 701 elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Elicitation of Potent Neutralizing 705

Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Single-component, self-assembling, protein nanoparticles presenting the 709 receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates

Single-dose immunisation 713 with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and 714 protective response in mice

Neutralizing antibody vaccine for pandemic 717 and pre-emergent coronaviruses

Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient 721

Adenovirus receptors: implications for targeting of viral vectors

Worldwide increased prevalence of human adenovirus type 3 (HAdV-3) respiratory infections 726 is well correlated with heterogeneous hypervariable regions (HVRs) of hexon

Anti-729 adenovirus humoral responses influence on the efficacy of vaccines based on epitope display 730 on adenovirus capsid

Humoral Responses Elicited by Adenovirus Displaying Epitopes Are Induced 733 Independently of the Infection Process and Shaped by the Toll-Like Receptor/MyD88 734 Pathway

Feedback regulation by IgG antibodies

Role of nanoscale antigen 739 organization on B-cell activation probed using DNA origami

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-744 electron microscopy

Structural analysis was performed by

Immunological characterization and virus neutralization was performed 754 by A.A, I.B. and M.B With input from all authors, P.F and P.P wrote the manuscript

We are grateful to the 'CNRS Prematuration program', to the 'ANR-Flash COVID' and to 758 'Région Auvergne Rhône-Alpes, AuRA' for the financial support to this work

Horizon 2020 research and innovation program (grant agreement No 682286). D.H is supported 761 by GEFLUC Dauphiné-Savoie, Ligue contre le Cancer Comité Isère

Alpes IDEX Initiatives de Recherche Stratégiques and Fondation du Souffle-Fonds de 763

We thank Aymeric Peuch for help with the usage 764 of the EM computing cluster and Emmanuelle Neumann for the training of CC in negative 765 staining and Leandro Estrozi for help with image analysis. We thank Philippe Mas

Dylon for help with statistical analysis. We would like to 767 thank David Nemazee for HeLa-ACE2 cells and SARS-CoV-2 spike expression plasmid

Pierre Charneau for plasmids encoding for lentiviral proteins and luciferase

Lupo for the COVID-19 patients cohort study. This work used the 770 platforms of the Grenoble Instruct-ERIC centre (ISBG

within the Grenoble Partnership for Structural Biology (PSB), supported by FRISBI

The electron 774 microscope facility is supported by the Auvergne-Rhône-Alpes Region

Recherche Medicale (FRM), the fonds FEDER and the GIS-Infrastructures en Biologie Sante

et Agronomie (IBISA). IBS acknowledges integration into the Interdisciplinary Research

V.D is an internship of Master de Biologie

Figure 1: Application of the SpyTag/SpyCatcher cross-linking method to the ADDomer 784 technology. (a) Diagram showing the internal insertion of SpyTag in the internal loop of an 785

Structure of a SpyTag covalently linked to a SpyCatcher is shown on the right (PDB 787 code: 4MLI) (b) SDS-PAGE profile of reduced and boiled samples of ADD-ST after interaction 788 with incremental ratio of SC showing the apparition of a higher MW covalent adduct

Electrospray ionization graphs of ADD-ST and ADD-ST/SC showing the shift of 790 the peaks by 13.3 kDa. The doublet is due to an alternative start of translation in ADD-ST and 791 display the same mass shift of 13,3kDa. (d) Negative staining electron micrographs of

Section through the density of the 3D 796 reconstruction without (ADD-ST) or with SC (ADD-ST/SC). (c) Isosurface representation of 797 the ADDomer-ST/SC 3D structure showing the extra density of SC in purple onto the non-798 decorated ADD-ST scaffold in light blue. The particle is represented along either the 5 or 3 799 fold-axis (left and right, upper panel; bars: 80 and 20Å, respectively)

SC along the 3-fold axis of the particle (upper panel) and comparison with SARS-CoV-2 RBD 804 architecture